Master Alliance Provisions Guide (MAPGuide)

Novavax – US Army Agreement for Research & Development of COVID-19 Vaccine

  • Access to medicines | Supply/Purchase of Products

SOW 10.0 Ensuring Sufficient Supply of the Product

a. In recognition of the Government’s significant funding for the development and manufacturing of the product in this Project Agreement and the Government’s need to provide sufficient quantities of a safe and effective COVID-19 vaccine to protect the United States population, the Government shall have the remedy described in this section to ensure sufficient supply of the product to meet the needs of the public health or national security. This remedy is not available to the Government unless and until both of the following conditions are met:

  • (i) Novavax gives written notice, required to be submitted to the Government no later than 15 business days, of: 
    • a. any formal management decision to terminate manufacturing of the NVXCoV-2373 vaccine prior to delivery of 100 million doses to USG; 
    • b. any formal management decision to discontinue sale of the NVX-CoV2373 vaccine to the Government prior to delivery of 100 million doses to USG; or 
    • c. any filing that anticipates Federal bankruptcy protection; and 
  • (ii) Novavax has submitted an Emergency Use Authorization under §564 of the FD&C Act or a biologics license application provisions of §351(a) of the Public Health Service Act (PHSA). 

b. If both conditions listed in section (a) occur, Novavax, upon the request of the Government, shall provide the following items necessary for the Government to pursue manufacturing of the NVX-CoV-2373 vaccine with a third party for exclusive sale to the U.S. Government:

    • i. a writing evidencing a non-exclusive, nontransferable, irrevocable (except for cause), royalty-free paid-up license to practice or have practiced for or on behalf of the U.S. Government any Background IP as defined in clause 7.1 necessary to manufacture or have manufactured the NVX-CoV2373 vaccine; 
    • ii. necessary FDA regulatory filings or authorizations owned or controlled by Novavax related to NVX-Cov2373 and any confirmatory instrument pertaining thereto; and 
    • iii. any outstanding Deliverables contemplated or materials purchased under this Project Agreement. 

c. This Article shall be incorporated into any contract for follow-on activities for the Government to acquire and use additional doses of the product. Per section 1.3, the estimated quantity for follow-on production/procurement is approximately 560 million doses. 

d. This Article will survive the acquisition or merger of the Contractor by or with a third party. This Article will survive the expiration of this agreement.